
Aerpio Pharmaceuticals, Inc. Long-Term Debt 2011-2026 | ARPO
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 125 K | 110 K | 85 K | 60 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 125 K | 60 K | 95 K |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
69.3 M | $ 15.6 | -5.71 % | $ 3.72 B | ||
|
AgeX Therapeutics
AGE
|
13.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
137 M | $ 3.55 | -2.34 % | $ 1.06 B | ||
|
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
130 K | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
16.6 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
93.3 M | $ 20.14 | 1.41 % | $ 2.54 B | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
309 M | $ 75.28 | -1.63 % | $ 1.45 B | ||
|
Applied Therapeutics
APLT
|
38 K | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
47.9 M | $ 1.47 | -9.81 % | $ 375 M | ||
|
Aravive
ARAV
|
1.88 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - | ||
|
Athersys
ATHX
|
8.76 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
12.7 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
118 M | $ 160.48 | -2.19 % | $ 7.98 B | ||
|
BridgeBio Pharma
BBIO
|
2.01 B | $ 65.44 | -1.65 % | $ 12.5 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
171 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
78.5 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
962 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
25.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
22.7 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
2.74 M | $ 2.75 | -2.14 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
436 K | $ 60.53 | 0.17 % | $ 11.6 B | ||
|
Cabaletta Bio
CABA
|
1.46 M | $ 3.19 | -7.14 % | $ 3.73 M | ||
|
AIkido Pharma
AIKI
|
2.63 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
12.8 M | $ 2.98 | -7.03 % | $ 1.07 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
1.49 M | $ 25.34 | -0.65 % | $ 679 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
5.02 M | $ 34.35 | -3.75 % | $ 3.57 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
16 M | $ 8.02 | -4.75 % | $ 34.7 M |